Kevin Feeley Sells 3,749 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,749 shares of GeneDx stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79. Following the transaction, the chief financial officer now directly owns 8,492 shares in the company, valued at approximately $821,261.32. This trade represents a 30.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total value of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Stock Down 4.1 %

Shares of WGS traded down $4.01 during midday trading on Monday, hitting $94.46. The company had a trading volume of 668,407 shares, compared to its average volume of 612,654. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -48.19 and a beta of 1.91. GeneDx Holdings Corp. has a 52 week low of $7.72 and a 52 week high of $115.60. The company’s 50 day moving average price is $84.69 and its 200 day moving average price is $70.37. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. On average, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Trading of GeneDx

Several institutional investors have recently added to or reduced their stakes in the business. MCF Advisors LLC grew its holdings in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its position in GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after purchasing an additional 316 shares during the period. Global Retirement Partners LLC bought a new position in GeneDx during the 4th quarter worth $28,000. Lazard Asset Management LLC bought a new stake in GeneDx in the fourth quarter valued at $35,000. Finally, Comerica Bank acquired a new position in shares of GeneDx during the fourth quarter valued at $50,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on WGS shares. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen boosted their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.